News

02 June 2015

NovaMedica and Ferring Pharmaceuticals bring innovative gastroenterological products from Switzerland to Russia

NovaMedica, a Russian pharmaceutical company, and Ferring Pharmaceuticals, a Swiss-based global biopharmaceutical company, have signed an agreement, that gives NovaMedica the rights for commercialization of a range of Ferring’s line of innovative gastroenterological prescription drug products for the treatment of inflammatory bowel disease (IBD) in the Russian market.

27 May 2015

NovaMedica is Expanding Ophta Horizons

NovaMedica, a Russian pharmaceutical company, participated in the White Nights-2015 International Ophthalmology Congress and hosted a satellite symposium “NovaMedica: New Ophta Horizons”. The symposium was started by Boris Malyugin, Deputy General Director for Science at MNTK “Eye Microsurgery” named after Federov S.N., and presented the first publication of in vitro research results on potency of netilmicin and reference drug products.

13 April 2015

People, medicines and venture investments

April 6-10, 2015, Moscow hosted the 22^nd Russian National Congress “People and Medicines”. NovaMedica have actively participated in R&D part of its program and organized a symposium “Venture investments in Research and Development” chaired by Mikhail Getman, Vice President for Pharmaceutical Operations at NovaMedica.

22 January 2015

Omega Pharma and NovaMedica to market a line of gastrointestinal products under BenegastTM brand in Russia

Russian pharmaceutical company NovaMedica and Omega Pharma, a Belgium-based pan-European pharmaceutical company specializing in the development and sale of over-the-counter (OTC) health and personal care products, have signed a partnership agreement granting NovaMedica exclusive rights to promote, distribute and sell a line of OTC gastrointestinal products under the Benegast^TM umbrella brand in Russia.

25 September 2014

Horus Pharma and NovaMedica sign agreement to market a portfolio of eye care products in Russia

NovaMedica LLC, a Russian pharmaceutical company, and Horus Pharma SL, a French company dedicated to the development of innovative products treating ophthalmic diseases, have signed a partnership agreement that grants NovaMedica exclusive rights to commercialize a portfolio of products in Russia and the Commonwealth of Independent States (CIS). 

18 June 2014

Vladimir Gurdus to speak about latest developments of RMI and NovaMedica projects at 20th Pharmaceutical Forum in St. Petersburg

“We have worked our way up from the concept of the RMI portfolio building to first sales of NovaMedica pharmaceutical company within two years’ time. This pace of development is considered fast in the pharmaceutical industry”, - Vladimir Gurdus, CEO, RMI Partners, Management Company of RMI and NovaMedica said during his speech at 20^th Russian Pharmaceutical Forum in St. Petersburg.

25 March 2014

SIFI and NovaMedica sign agreement to market eight eye care products in Russia

Leading Italian developer of innovative eye care solutions S.I.F.I. S.p.A. (SIFI) and Russian pharmaceutical company NovaMedica have entered into an exclusive commercial agreement  for NovaMedica to market eight products developed and licensed by SIFI for the treatment of a wide range of ophthalmic pathologies in Russia and the CIS.

04 February 2014

NovaMedica and Skolkovo Foundation Sign Agreement to Build R&D center

NovaMedica Innotech, R&D unit of NovaMedica, a Russian pharmaceutical resident company of the Skolkovo Innovation Center, and Skolkovo Foundation signed the agreement to collaborate in building R&D center on the territory of Skolkovo Technopark.

19 December 2013

Nuvo Research® and NovaMedica sign agreement to market Pennsaid® in Russia

Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of products in the areas of topical pain and immunology, and NovaMedica LLC (NovaMedica), a Russian pharmaceutical company, today announced that they have signed a supply and distribution agreement providing NovaMedica the exclusive rights to market and sell Nuvo’s Pennsaid 1.5% and Pennsaid 2% products in Russia and some of the Community of Independent States (CIS).  

11 December 2013

Venter Pharma and NovaMedica Sign Agreement to Commercialize New Lactose Intolerance Test in Russia

NovaMedica LLC, a Russian pharmaceutical  company, and Venter Pharma SL, a Spanish company, developing innovative diagnostic systems, have signed a partnership agreement that grants NovaMedica exclusive rights to commercialize a new technology for the diagnosis of lactose intolerance,  LacTEST®, in Russia and the Community of Independent States (CIS).